Ranbaxy Laboratories has elevated Atul Sobti to the position of chief operating officer (COO) effective January 01, 2007.
According to a release issued by Ranbaxy to the BSE, Sobti will be responsible for global business operations, manufacturing and generic development. He will continue to report to Malvinder Singh, CEO and MD of the company.
Announcing Sobti’s appointment, Singh said: "With continued aggressive growth plans in 2007 and beyond, we need to ensure an integrated, cohesive and cost effective organisation globally with greater interaction and seamless interface amongst all facets of the value adding process from the lab to market. The COO's position will effectively bring about these improved efficiencies by integrating leadership and accountability for the global P&L."
Sobti spearheaded the company's Asian territory as president Asia (API sales & purchasing and GCHC).